Top

Cancer Cell International

Published in:

Open Access 01-12-2022 | Hepatocellular Carcinoma | Primary research

Piezo1 promoted hepatocellular carcinoma progression and EMT through activating TGF-β signaling by recruiting Rab5c

Authors: Yi-ming Li, Cong Xu, Bo Sun, Fang-jing Zhong, Momo Cao, Lian-yue Yang

Published in: Cancer Cell International | Issue 1/2022

Abstract

Background

Piezo1 has been revealed to play a regulatory role in vascular development and progression of variety tumors. However, whether and how the progression of hepatocellular carcinoma (HCC) regulated by Piezo1 remains elusive. This study aimed to elucidate the effect and mechanisms of Piezo1 in HCC.

Methods

The mRNA and protein expression level of Piezo1 in HCC samples and cell lines was determined by qRT-PCR, western blot and immunohistochemistry analyses. Two independent study cohorts containing 280 patients were analyzed to reveal the association between Piezo1 expression and clinicopathological characteristics. Series of in vitro and in vivo experiments were used to validate the function of Piezo1 in HCC. Gene set enrichment analysis (GSEA) was performed to explore the signaling pathway of Piezo1. Immunoprecipitation, immunofluorescence and in vitro and in vivo experiments were used to explore the molecular mechanism of Piezo1 in HCC progression.

Results

Our results demonstrated the Piezo1 expression was significantly upregulated in HCC tissues and cell lines, and upregulation of Piezo1 closely correlated with aggressive clinicopathological features and poor prognosis. Knockdown of Piezo1 in HCCLM3 and Hep3B cells significantly restrained proliferation, migration, invasion and epithelial–mesenchymal transition (EMT) of HCC cells in vitro, and tumor growth, metastasis, EMT in vivo. TGF-β signaling pathway was most significant enriched pathway in GSEA. Finally, tumor promotion effect of Piezo1 was found to exerted through recruiting and combining Rab5c to activating TGF-β signaling pathway.

Conclusions

Piezo1 significantly related to poor prognosis and promotes progression of hepatocellular carcinoma via activating TGF-β signaling, which suggesting that Piezo1 may serve as a novel prognostic predictor and the potential therapeutic target for HCC patients.

Available only for authorised users

Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492[publishedOnlineFirst:2018/09/13].CrossRefPubMed

Zhou J, Sun H, Wang Z, et al. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition). Liver Cancer. 2020;9(6):682–720. https://doi.org/10.1159/000509424.CrossRefPubMedPubMedCentral

Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604. https://doi.org/10.1038/s41575-019-0186-y.CrossRefPubMedPubMedCentral

Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–14. https://doi.org/10.1016/S0140-6736(18)30010-2.CrossRefPubMed

Sun Y, Wu L, Zhong Y, et al. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. Cell. 2020. https://doi.org/10.1016/j.cell.2020.11.041.CrossRefPubMedPubMedCentral

Yang LY, Fang F, Ou DP, et al. Solitary large hepatocellular carcinoma: a specific subtype of hepatocellular carcinoma with good outcome after hepatic resection. Ann Surg. 2009;249(1):118–23. https://doi.org/10.1097/SLA.0b013e3181904988.CrossRefPubMed

Tsilimigras DI, Mehta R, Paredes AZ, et al. Overall tumor burden dictates outcomes for patients undergoing resection of multinodular hepatocellular carcinoma beyond the Milan criteria. Ann Surg. 2020;272(4):574–81. https://doi.org/10.1097/SLA.0000000000004346.CrossRefPubMed

Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019;156(2):477-91 e1. https://doi.org/10.1053/j.gastro.2018.08.065.CrossRefPubMed

Bruix J, Tak W-Y, Gasbarrini A, et al. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. EurJ Cancer (Oxford, England: 1990). 2013;49(16):3412–9. https://doi.org/10.1016/j.ejca.2013.05.028.CrossRef

10.

Burrel M, Reig M, Forner A, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol. 2012;56(6):1330–5. https://doi.org/10.1016/j.jhep.2012.01.008.CrossRefPubMed

11.

Luo YD, Fang L, Yu HQ, et al. p53 haploinsufficiency and increased mTOR signalling define a subset of aggressive hepatocellular carcinoma. J Hepatol. 2021;74(1):96–108. https://doi.org/10.1016/j.jhep.2020.07.036.CrossRefPubMed

12.

He K, Yan X, Li N, et al. Internalization of the TGF-β type I receptor into caveolin-1 and EEA1 double-positive early endosomes. Cell Res. 2015;25(6):738–52. https://doi.org/10.1038/cr.2015.60.CrossRefPubMedPubMedCentral

13.

Yang H, Fang F, Chang R, et al. MicroRNA-140-5p suppresses tumor growth and metastasis by targeting transforming growth factor beta receptor 1 and fibroblast growth factor 9 in hepatocellular carcinoma. Hepatology. 2013;58(1):205–17. https://doi.org/10.1002/hep.26315.CrossRefPubMed

14.

Xiao S, Chang RM, Yang MY, et al. Actin-like 6A predicts poor prognosis of hepatocellular carcinoma and promotes metastasis and epithelial-mesenchymal transition. Hepatology. 2016;63(4):1256–71. https://doi.org/10.1002/hep.28417.CrossRefPubMed

15.

Gao Q, Zhu H, Dong L, et al. Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma. Cell. 2019. https://doi.org/10.1016/j.cell.2019.08.052.CrossRefPubMedPubMedCentral

16.

Coste B, Mathur J, Schmidt M, et al. Piezo1 and Piezo2 are essential components of distinct mechanically activated cation channels. Science. 2010;330(6000):55–60. https://doi.org/10.1126/science.1193270.CrossRefPubMedPubMedCentral

17.

Solis AG, Bielecki P, Steach HR, et al. Mechanosensation of cyclical force by PIEZO1 is essential for innate immunity. Nature. 2019;573(7772):69–74. https://doi.org/10.1038/s41586-019-1485-8.CrossRefPubMedPubMedCentral

18.

Liu Q, Sun B, Zhao J, et al. Increased Piezo1 channel activity in interstitial Cajal-like cells induces bladder hyperactivity by functionally interacting with NCX1 in rats with cyclophosphamide-induced cystitis. Exp Mol Med. 2018. https://doi.org/10.1038/s12276-018-0088-z.CrossRefPubMedPubMedCentral

19.

Romac JM, Shahid RA, Swain SM, et al. Piezo1 is a mechanically activated ion channel and mediates pressure induced pancreatitis. Nat Commun. 2018;9(1):1715. https://doi.org/10.1038/s41467-018-04194-9.CrossRefPubMedPubMedCentral

20.

Blythe NM, Muraki K, Ludlow MJ, et al. Mechanically activated Piezo1 channels of cardiac fibroblasts stimulate p38 mitogen-activated protein kinase activity and interleukin-6 secretion. J Biol Chem. 2019;294(46):17395–408. https://doi.org/10.1074/jbc.RA119.009167.CrossRefPubMedPubMedCentral

21.

Li J, Hou B, Tumova S, et al. Piezo1 integration of vascular architecture with physiological force. Nature. 2014;515(7526):279–82. https://doi.org/10.1038/nature13701.CrossRefPubMedPubMedCentral

22.

Gudipaty SA, Lindblom J, Loftus PD, et al. Mechanical stretch triggers rapid epithelial cell division through Piezo1. Nature. 2017;543(7643):118–21. https://doi.org/10.1038/nature21407.CrossRefPubMedPubMedCentral

23.

Pathak MM, Nourse JL, Tran T, et al. Stretch-activated ion channel Piezo1 directs lineage choice in human neural stem cells. Proc Natl Acad Sci U S A. 2014;111(45):16148–53. https://doi.org/10.1073/pnas.1409802111.CrossRefPubMedPubMedCentral

24.

Choi D, Park E, Jung E, et al. Piezo1 incorporates mechanical force signals into the genetic program that governs lymphatic valve development and maintenance. JCI Insight. 2019. https://doi.org/10.1172/jci.insight.125068.CrossRefPubMedPubMedCentral

25.

Zhang J, Zhou Y, Huang T, et al. PIEZO1 functions as a potential oncogene by promoting cell proliferation and migration in gastric carcinogenesis. Mol Carcinog. 2018;57(9):1144–55. https://doi.org/10.1002/mc.22831.CrossRefPubMed

26.

Li C, Rezania S, Kammerer S, et al. Piezo1 forms mechanosensitive ion channels in the human MCF-7 breast cancer cell line. Sci Rep. 2015;5:8364. https://doi.org/10.1038/srep08364.CrossRefPubMedPubMedCentral

27.

Suzuki T, Muraki Y, Hatano N, et al. PIEZO1 channel is a potential regulator of synovial sarcoma cell-viability. Int J Mol Sci. 2018. https://doi.org/10.3390/ijms19051452.CrossRefPubMedPubMedCentral

28.

Qu S, Li S, Hu Z. Upregulation of Piezo1 Is a novel prognostic indicator in glioma patients. Cancer Manag Res. 2020;12:3527–36. https://doi.org/10.2147/CMAR.S251776.CrossRefPubMedPubMedCentral

29.

Siegert AM, Serra-Peinado C, Gutierrez-Martinez E, et al. Altered TGF-beta endocytic trafficking contributes to the increased signaling in Marfan syndrome. Biochim Biophys Acta Mol Basis Dis. 2018;1864(2):554–62. https://doi.org/10.1016/j.bbadis.2017.11.015.CrossRefPubMed

30.

Wang JL, Yang MY, Xiao S, et al. Downregulation of castor zinc finger 1 predicts poor prognosis and facilitates hepatocellular carcinoma progression via MAPK/ERK signaling. J Exp Clin Cancer Res. 2018;37(1):45. https://doi.org/10.1186/s13046-018-0720-8.CrossRefPubMedPubMedCentral

31.

Terpe HJ, Störkel S, Zimmer U, et al. Expression of CD44 isoforms in renal cell tumors. Positive correlation to tumor differentiation. Am J Pathol. 1996;148(2):453–63.PubMedPubMedCentral

32.

Liu L, Dai Y, Chen J, et al. Maelstrom promotes hepatocellular carcinoma metastasis by inducing epithelial-mesenchymal transition by way of Akt/GSK-3β/Snail signaling. Hepatology. 2014;59(2):531–43. https://doi.org/10.1002/hep.26677.CrossRefPubMed

33.

Chang RM, Yang H, Fang F, et al. MicroRNA-331-3p promotes proliferation and metastasis of hepatocellular carcinoma by targeting PH domain and leucine-rich repeat protein phosphatase. Hepatology. 2014;60(4):1251–63. https://doi.org/10.1002/hep.27221.CrossRefPubMed

34.

Chang RM, Xiao S, Lei X, et al. miRNA-487a promotes proliferation and metastasis in hepatocellular carcinoma. Clin Cancer Res. 2017;23(10):2593–604. https://doi.org/10.1158/1078-0432.CCR-16-0851.CrossRefPubMed

35.

Liu H, Bian W, Yang D, et al. Inhibiting the Piezo1 channel protects microglia from acute hyperglycaemia damage through the JNK1 and mTOR signalling pathways. Life Sci. 2021;264: 118667. https://doi.org/10.1016/j.lfs.2020.118667.CrossRefPubMed

36.

Bagriantsev SN, Gracheva EO, Gallagher PG. Piezo proteins: regulators of mechanosensation and other cellular processes. J Biol Chem. 2014;289(46):31673–81. https://doi.org/10.1074/jbc.R114.612697.CrossRefPubMedPubMedCentral

37.

Saotome K, Murthy SE, Kefauver JM, et al. Structure of the mechanically activated ion channel Piezo1. Nature. 2018;554(7693):481–6. https://doi.org/10.1038/nature25453.CrossRefPubMed

38.

Yang XN, Lu YP, Liu JJ, et al. Piezo1 is as a novel trefoil factor family 1 binding protein that promotes gastric cancer cell mobility in vitro. Dig Dis Sci. 2014;59(7):1428–35. https://doi.org/10.1007/s10620-014-3044-3.CrossRefPubMed

39.

Aykut B, Chen R, Kim JI, et al. Targeting Piezo1 unleashes innate immunity against cancer and infectious disease. Sci Immunol. 2020. https://doi.org/10.1126/sciimmunol.abb5168.CrossRefPubMed

40.

McHugh BJ, Buttery R, Lad Y, et al. Integrin activation by Fam38A uses a novel mechanism of R-Ras targeting to the endoplasmic reticulum. J Cell Sci. 2010;123(Pt 1):51–61. https://doi.org/10.1242/jcs.056424.CrossRefPubMed

41.

Wang X, Wu WKK, Gao J, et al. Autophagy inhibition enhances PD-L1 expression in gastric cancer. J Exp Clin Cancer Res. 2019;38(1):140. https://doi.org/10.1186/s13046-019-1148-5.CrossRefPubMedPubMedCentral

42.

Hasegawa K, Fujii S, Matsumoto S, et al. YAP signaling induces PIEZO1 to promote oral squamous cell carcinoma cell proliferation. J Pathol. 2020. https://doi.org/10.1002/path.5553.CrossRefPubMed

43.

Sun Y, Li M, Liu G, et al. The function of Piezo1 in colon cancer metastasis and its potential regulatory mechanism. J Cancer Res Clin Oncol. 2020;146(5):1139–52. https://doi.org/10.1007/s00432-020-03179-w.CrossRefPubMedPubMedCentral

44.

Cai Q, Wang S, Jin L, et al. Long non-coding RNA GBCDRlnc1 induces chemoresistance of gallbladder cancer cells by activating autophagy. Mol Cancer. 2019;18(1):82. https://doi.org/10.1186/s12943-019-1016-0.CrossRefPubMedPubMedCentral

45.

Wang W, Yang LY, Huang GW, et al. Genomic analysis reveals RhoC as a potential marker in hepatocellular carcinoma with poor prognosis. Br J Cancer. 2004;90(12):2349–55.CrossRef

46.

Yang L-Y, Wang W, Peng J-X, et al. Differentially expressed genes between solitary large hepatocellular carcinoma and nodular hepatocellular carcinoma. World J Gastroenterol. 2004;10(24):3569–73.CrossRef

47.

Yang L, Xu J, Ou D, et al. Hepatectomy for huge hepatocellular carcinoma: single institute’s experience. World J Surg. 2013;37(9):2189–96. https://doi.org/10.1007/s00268-013-2095-5.CrossRefPubMed

48.

Yang L-Y, Chang R-M, Lau W-Y, et al. Mesohepatectomy for centrally located large hepatocellular carcinoma: indications, techniques, and outcomes. Surgery. 2014;156(5):1177–87. https://doi.org/10.1016/j.surg.2014.05.012.CrossRefPubMed

49.

Zhao YR, Wang JL, Xu C, et al. HEG1 indicates poor prognosis and promotes hepatocellular carcinoma invasion, metastasis, and EMT by activating Wnt/beta-catenin signaling. Clin Sci (Lond). 2019;133(14):1645–62. https://doi.org/10.1042/CS20190225.CrossRef

50.

Kang H, Hong Z, Zhong M, et al. Piezo1 mediates angiogenesis through activation of MT1-MMP signaling. Am J Physiol Cell Physiol. 2019. https://doi.org/10.1152/ajpcell.00346.2018.CrossRefPubMed

51.

Zhao L, Li J, Liu Y, et al. Flotillin1 promotes EMT of human small cell lung cancer via TGF-beta signaling pathway. Cancer Biol Med. 2018;15(4):400–14. https://doi.org/10.20892/j.issn.2095-3941.2018.0053.CrossRefPubMedPubMedCentral

52.

Fuxe J, Karlsson M. TGF-β-induced epithelial-mesenchymal transition: a link between cancer and inflammation. Semin Cancer Biol. 2012;22:455–61. https://doi.org/10.1016/j.semcancer.2012.05.004.CrossRefPubMed

53.

Thakur AK, Nigri J, Lac S, et al. TAp73 loss favors Smad-independent TGF-beta signaling that drives EMT in pancreatic ductal adenocarcinoma. Cell Death Differ. 2016;23(8):1358–70. https://doi.org/10.1038/cdd.2016.18.CrossRefPubMedPubMedCentral

54.

Liu S, Xu X, Fang Z, et al. Piezo1 impairs hepatocellular tumor growth via deregulation of the MAPK-mediated YAP signaling pathway. Cell Calcium. 2021;95: 102367. https://doi.org/10.1016/j.ceca.2021.102367.CrossRefPubMed

55.

Seoane J, Gomis RR. TGF-beta family signaling in tumor suppression and cancer progression. Cold Spring Harb Perspect Biol. 2017. https://doi.org/10.1101/cshperspect.a022277.CrossRefPubMedPubMedCentral

56.

Fattet L, Yang J. RREB1 integrates TGF-beta and RAS signals to drive EMT. Dev Cell. 2020;52(3):259–60. https://doi.org/10.1016/j.devcel.2020.01.020.CrossRefPubMed

57.

Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 2009;19(2):156–72. https://doi.org/10.1038/cr.2009.5.CrossRefPubMed

58.

Syed V. TGF-beta signaling in cancer. J Cell Biochem. 2016;117(6):1279–87. https://doi.org/10.1002/jcb.25496.CrossRefPubMed

59.

Mitchell H, Choudhury A, Pagano RE, et al. Ligand-dependent and -independent transforming growth factor-beta receptor recycling regulated by clathrin-mediated endocytosis and Rab11. Mol Biol Cell. 2004;15(9):4166–78. https://doi.org/10.1091/mbc.e04-03-0245.CrossRefPubMedPubMedCentral

60.

Heng J, Lv P, Zhang Y, et al. Rab5c-mediated endocytic trafficking regulates hematopoietic stem and progenitor cell development via Notch and AKT signaling. PLoS Biol. 2020;18(4): e3000696. https://doi.org/10.1371/journal.pbio.3000696.CrossRefPubMedPubMedCentral

61.

Mendoza P, Ortiz R, Díaz J, et al. Rab5 activation promotes focal adhesion disassembly, migration and invasiveness in tumor cells. J Cell Sci. 2013;126(Pt 17):3835–47. https://doi.org/10.1242/jcs.119727.CrossRefPubMedPubMedCentral

62.

Onodera Y, Nam J-M, Hashimoto A, et al. Rab5c promotes AMAP1-PRKD2 complex formation to enhance β1 integrin recycling in EGF-induced cancer invasion. J Cell Biol. 2012;197(7):983–96. https://doi.org/10.1083/jcb.201201065.CrossRefPubMedPubMedCentral

63.

Takeda M, Koseki J, Takahashi H, et al. Disruption of endolysosomal RAB5/7 efficiently eliminates colorectal cancer stem cells. Cancer Res. 2019;79(7):1426–37. https://doi.org/10.1158/0008-5472.CAN-18-2192.CrossRefPubMed

Title: Piezo1 promoted hepatocellular carcinoma progression and EMT through activating TGF-β signaling by recruiting Rab5c
Authors: Yi-ming Li
Cong Xu
Bo Sun
Fang-jing Zhong
Momo Cao
Lian-yue Yang
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Hepatocellular Carcinoma
Hepatocellular Carcinoma
Published in: Cancer Cell International / Issue 1/2022
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-022-02574-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2022

Integrated regulation of chondrogenic differentiation in mesenchymal stem cells and differentiation of cancer cells

Correction to: NAP1L1 interacts with hepatoma-derived growth factor to recruit c-Jun inducing breast cancer growth

Spatial maps of hepatocellular carcinoma transcriptomes highlight an unexplored landscape of heterogeneity and a novel gene signature for survival

FERMT1 contributes to the migration and invasion of nasopharyngeal carcinoma through epithelial–mesenchymal transition and cell cycle arrest

Molecular mechanism by which CDCP1 promotes proneural-mesenchymal transformation in primary glioblastoma

β-Elemene alleviates cisplatin resistance in oral squamous cell carcinoma cell via inhibiting JAK2/STAT3 pathway in vitro and in vivo

Keynote webinar | Spotlight on antibody–drug conjugates in cancer